Pulmonx Corporation (LUNG) Q4 2024 Earnings Call Transcript
Pulmonx Corporation (NASDAQ:LUNG) Q4 2024 Results Conference Call February 19, 2025 4:30 PM ET
Company Participants
Elizabeth Sparicio – Investor Relations
Steve Williamson – President and Chief Executive Officer
Mehul Joshi – Chief Financial Officer
Conference Call Participants
Frank Takkinen – Lake Street Capital Markets
Jon Young – Canaccord
Larry Biegelsen – Wells Fargo
Joanne Wuensch – Citi
Joseph Downing – Piper Sandler
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Pulmonx Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would like now to turn the conference over to the first speaker today, Elizabeth Sparicio, Investor Relations. Please go ahead.
Elizabeth Sparicio
Good afternoon, and thank you all for participating in today’s call.
Joining me from Pulmonx are Steve Williamson, President and Chief Executive Officer; and Mehul Joshi, Chief Financial Officer. Earlier today, Pulmonx issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is available on Pulmonx’s website.
Before we begin, I’d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our operating trends, commercial strategies, and future financial performance, the timing and results of clinical trials, expense management, market opportunity, guidance for revenue, gross margin and operating expenses, commercial expansion, and product pipeline development are based upon our current estimates and various assumptions.
